Will bedaquiline be reimbursed by medical insurance?

Bedaquiline (Bedaquiline) is an innovative anti-tuberculosis drug specifically used to treat multidrug-resistant tuberculosis (MDR-TB). It was developed by Janssen Pharmaceuticals and was accelerated approval by the US FDA in 2012, making it the first new anti-tuberculosis drug approved in the past 40 years. Its unique mechanism of action inhibits the ATP synthase of Mycobacterium tuberculosis, thereby blocking the energy production of the bacteria, leading to the death of the bacteria. This mechanism of action is different from other traditional anti-tuberculosis drugs, making it particularly suitable for use in drug-resistant cases, greatly improving the success rate of treatment.

Bedaquiline is usually given in combination with other anti-tuberculosis drugs over a course of 24 weeks (about 6 months). Research and clinical practice have shown that bedaquiline can significantly shorten the treatment time of tuberculosis and improve the cure rate of multidrug-resistant tuberculosis. However, the drug needs to be used with caution as it may cause some adverse reactions, such as QT interval prolongation (risk of abnormal heart rhythm), abnormal liver function, headache, nausea, etc. Therefore, patients need to be strictly monitored by doctors while receiving treatment, and have regular electrocardiograms and liver function tests.

Regarding medical insurance reimbursement, bedaquiline has been launched in China and has been successfully included in the national medical insurance directory, which has greatly reduced the financial burden on patients. In China, the common specification is 100mg*24 tablets, and the price per box is about six to seven thousand yuan. Since the cost will be significantly reduced after being included in medical insurance, the specific reimbursement ratio and price need to be determined according to the local medical insurance policy and the relevant regulations of the hospital pharmacy. Generally, medical insurance reimbursement policies vary from region to region. It is recommended that patients consult local hospitals or medical insurance departments in detail to obtain the most accurate information.

In addition, in the international market, the price of bedaquiline varies greatly between different countries and versions. For example, the price of the Russian version of the original drug 100mg*188 tablets is more than 10,000 yuan, which is more economical than the domestic price, while the Indian generic drug 100mg*188 tablets only cost more than 2,000 yuan, which is basically the same as the ingredients of the original drug. However, attention must be paid to the reliability of imported drugs.

Overall, bedaquiline offers new hope for patients with multidrug-resistant tuberculosis. After being covered by medical insurance, the patient's burden is significantly reduced, but the doctor's instructions must be strictly followed during the treatment process to ensure safety and efficacy.